Association of statin use and the risk of end-stage renal disease: A nationwide Asian population-based case-control study

Shih-Yi Lin; Cheng-Li Lin; Wu-Huei Hsu; Cheng-Chieh Lin; Chiz-Tzung Chang; Chia-Hung Kao

doi:10.1016/j.ejim.2016.02.012

Association of statin use and the risk of end-stage renal disease: A nationwide Asian population-based case-control study

Eur J Intern Med. 2016 Jun:31:68-72. doi: 10.1016/j.ejim.2016.02.012. Epub 2016 Feb 24.

Authors

Shih-Yi Lin¹, Cheng-Li Lin², Wu-Huei Hsu³, Cheng-Chieh Lin⁴, Chiz-Tzung Chang¹, Chia-Hung Kao⁵

Affiliations

¹ Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taiwan; Division of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, Taiwan.
² Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan.
³ Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taiwan; Division of Pulmonary and Critical Care Medicine, China Medical University Hospital and China Medical University, Taichung, , Taiwan.
⁴ Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taiwan; Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
⁵ Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taiwan; Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan. Electronic address: d10040@mail.cmuh.org.tw.

PMID: 26920930
DOI: 10.1016/j.ejim.2016.02.012

Abstract

Background: Although experimental models have shown that statins could alleviate glomerular damage and decrease urinary protein excretion, the renal effects of statins remain unclear. A case-control study was conducted using data from Taiwan's National Health Insurance system.

Methods: An end-stage renal disease (ESRD) group comprising 11,486 patients was established. Each patient was frequency-matched by age, sex, and comorbidities with one person without ESRD from the general population. Logistic regression analysis was performed to estimate the influence of statin use on ESRD risk.

Results: The overall adjusted odds ratios (ORs) of ESRD among patients who received statins was 1.59 (95% confidence interval=1.50-1.68). The raised ESRD risk of statin remained consolidated regardless of statin type (P<.001), except lovastatin. Further, while stratified by cumulative define daily dose, the risk of ESRD increased with accumulative dosage of statins (P for trend<.001).

Conclusion: This population-based case-control study showed that statin use might be associated with increased ESRD risks. Large-scale randomized clinical trial encompassing statins of different kinds and populations of different comorbidities would be helpful to clarify the potential ESRD risks of statin users.

Keywords: Case–control study; End-stage renal disease; Statins.

MeSH terms

Aged
Case-Control Studies
Comorbidity
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipidemias / drug therapy*
Kidney Failure, Chronic / epidemiology*
Kidney Failure, Chronic / etiology
Logistic Models
Male
Middle Aged
Odds Ratio
Risk Factors
Taiwan / epidemiology

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors